TriVentures

Michal Geva, a co-founder and Managing Partner, leads the investment team at TriVentures. She brings an operating background in the medical device industry, which shapes the firm's clinically grounded diligence process. Decision-making is centralized within a small partnership group based in Herzliya.

TriVentures sources primarily through the dense Israeli health-tech ecosystem, leveraging deep relationships with hospital innovation centers, serial health-tech entrepreneurs, and the Israel Innovation Authority. The firm's long tenure in a narrow niche means many deals come through founder referrals and clinician networks before reaching broader market visibility. Its absence from major tech conferences further reinforces a reliance on curated, offline sourcing.

TriVentures operates as a traditional venture capital firm raising capital from external limited partners, though it has maintained a deliberately small and discreet profile. It is not a single-family office or a corporate venture arm. The firm runs classic VC fund structures, though fund sizes and LP identities remain private.

TriVentures is exclusively a direct investor in early-stage operating companies. There is no public record of the firm making fund-of-fund commitments or investing as a limited partner in other venture capital managers. Its model is hands-on, board-level involvement in portfolio companies.

TriVentures concentrates on seed and early-stage rounds, occasionally participating in follow-on growth financings for existing portfolio companies. It does not pursue late-stage or pre-IPO rounds as a primary strategy. The firm writes first-check and second-check investment sizes, consistent with a seed-stage Israeli VC profile.

TriVentures is an independent entity and not a spinout from a larger fund or corporate group. It occasionally co-invests alongside other digital health-focused VCs and generalist Israeli funds, but maintains no formal affiliation. Its niche focus on digital health sets it apart from broader Israeli early-stage firms such as Pitango or aMoon, which cover wider technology or life-science mandates.

TriVentures regularly co-invests with US and European health-tech venture firms, particularly when portfolio companies require expertise in FDA clearance, reimbursement, or US hospital sales. These syndicates are often formed opportunistically rather than through a structured co-investor club. The firm's small fund size makes syndication a standard part of its strategy.